CYTOKINE PROFILE OF RAT BLOOD SERUM DURING EXPERIMENTAL BRONCHOPULMONARY INFLAMMATION AND IMMUNOMODULATOR ADMINISTRATION

E.V. Mokrenko1, 2, P.D. Shabanov2
1 C.M. Kirov Military Medical Academy, Saint Petersburg, Russia;
2 Irkutsk State Medical University, Irkutsk, Russia

Experimental bronchopneumonia was modeled by administering turpentine to the trachea under ether anesthesia. After the operation, the solution of one of the studied immunomodulators was intraperitoneally administered to the animals for 5 days (1 time/day): polyoxidonium — 0.75 mg/kg, trekrezan 25 mg/kg or metaprot 25 mg/kg. After decapitation, the interleukin profile was determined in the blood using commercial kits (Merk). Inflammation decreased blood concentrations of both proinflammatory factors (IL-1β, IL-2, IL-12, INF-γ and chemokine MCP-1), and anti-inflammatory (IL-4, IL-10) cytokines. At the same time, the levels of TNFα and IL-6, as well as the anti-inflammatory cytokine IL-13, increased. The introduction of immunomodulators, polyoxidonium, trekrezan or metaprot substantially normalized the level of pro- (IL-1β, IL-2, IL-12 (p7), chemokine MCP-1, INFα) and anti-inflammatory cytokines (IL-4, IL-10). The anti-inflammatory effect of drugs is associated with the normalization of cytokine metabolism.

Keywords: bronchopneumonia; cytokines; immunomodulators; polyoxidonium; trekrezan; metaprot.

Introduction. In recent years, immunomodulators have been actively used in bronchopulmonary inflammation, to prevent secondary immunodeficiency, disorders of energy metabolism and oxidative stress [2]. In previous studies [2, 5], the high protective effect of immunomodulators, polyoxidonium, trekrezan and metaprot in animals with experimental inflammation of bronchopulmonary tissue was shown. A number of immunopathological mechanisms that form the basis for the development of this process, mainly affecting the phagocytic immunity, have been clarified. In this work, we studied the nature of changes in the content of pro- and anti-inflammatory cytokines in the blood serum of rats in experimental bronchopulmonary inflammation and administration of immunomodulators, polyoxidonium, trekrezan and metaprot.

Material and methods. The experiments were performed on rats Wistar males weighing 200–250 g. All rats were divided into 5 groups (n = 13–18): 1) control; 2) with bronchopulmonary inflammation (BP); 3) BP + polyoxidonium 0.75 mg/kg; 4) BP + trekrezan 25 mg/kg; 5) BP + metaprot 25 mg/kg. Acute bronchopneumonia was reproduced by injecting 0.1 ml of gum turpentine into the rat trachea under ether anesthesia [2]. Immediately after the operation and further for 5 days (1 time per day), the test animals were in-
traperitoneally injected with a solution of one of the studied immunomodulators. On the 5th day of the experiment, the rats were decapitated, blood was taken, from which serum was prepared, the serum was frozen and stored at –20 °C until testing. The concentration of cytokines was determined by the method of protein multiplex analysis using flow immunofluorometry [3], Bio-Rad Laboratories instrument (USA). Used commercial kits Milliplex Map Rat Citokine/Chemokine (Merk) in accordance with the manufacturer’s instructions. Statistical processing of the results was performed using the standard software package Statistica for Windows 6.0.

Results and discussion. Experimental BP in rats, confirmed morphologically [2], was accompanied by significant changes in the content of cytokines in the blood serum, produced both by B- and by T <x₁> and Th <x₂> lymphocytes and other cells (Table 1). At the same time, concentrations of both pro-inflammatory (IL-1β, IL-2, IL-12, INF-γ and chemokine MCP-1) and anti-inflammatory factors (IL-4, IL-10) decreased in the blood. The levels of TNFα and IL-6, as well as the anti-inflammatory cytokine IL-13 (3 times) were elevated in the blood.

In general, experimental BP in rats contributed to the development of secondary immunodeficiency with a sharp inhibition of the immunoregulatory functions of cytokines. Thus, the content of TNFα, which is a powerful factor of excessive proliferation and enhancement of apoptosis, an inducer of the development of not only local, but also systemic inflammation [1], increased by more than 3 times. The high severity of the systemic inflammatory process is indicated by a 5-fold increase in the content of IL-6, which is a “damage cytokine” and produced not only by monocytes, but also by T cells, macrophages, fibroblasts and endothelial cells [4]. IL-6 activates B-lymphocytes with the formation of plasma cells and antibodies [1].

In the treatment of BP with immunomodulators, the mortality rate of animals decreased significantly. Thus, the rats’ survival rate with the introduction of polyoxidonium was 58%, trekrezan 65% and metaprot 60% compared with 48% survival in BP rats without drug administration. The course introduction of immunomodulators significantly limited the effect of the pathological process on the content of cytokines in the blood of rats. The level of pro-inflammatory cytokines IL-1β, IL-2, IL-12 (p7), as well as chemokine MCP-1 and INFα, as well as the anti-inflammatory cytokines IL-4, IL-10, IL-13 became significantly higher, which indicates partial restoration of immunoregulatory function and even expression of cytokine-producing properties of B-cells, T <x₁>, Th <x₂> cells of lymphocytes. The studied drugs significantly limited the cytotoxic effect of IL-6, one of the leading mediators of inflammation. Apparently, the sanogenetic mechanism of action of the studied drugs is the restoration of the production of anti-inflammatory cytokines IL-4 and IL-10.

Conclusion. Therefore, pharmacological agents used to reduce the severity of BP in rats exhibit the properties of true immunomodulators, helping to identify the protective properties of cytokines and providing a complex adaptive response of the body in severe inflammation in bronchopulmonary tissue.
References


